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panied by an accelerated focal glomerulosclerosis at day 21.Antibody-induced albuminuria and accelerated focal glomeru-
We suggest that the Thy-1.1 transgenic mouse is an excellentlosclerosis in the Thy-1.1 transgenic mouse.
model to study specifically the relation between podocytic injury,Background. Podocytes play an important role in the devel-
albuminuria and the development of focal glomerulosclerosis.opment of proteinuria and focal glomerulosclerosis. Previously
we have demonstrated that a combination of two monoclonal
antibodies (mAb) against aminopeptidase A (APA), an enzyme
present on podocytes, induces a massive acute albuminuria in In patients with renal diseases proteinuria is an impor-mice. The present study examined the relationship between
tant predictor of progressive renal failure [1, 2]. Focalthe acute antibody-induced albuminuria and the development
glomerulosclerosis is the hallmark of the glomerular le-of focal glomerulosclerosis in the Thy-1.1 transgenic mouse.
This mouse expresses a hybrid human-mouse Thy-1.1 antigen sion that is characteristically observed in failing kidneys,
on the podocytes, and slowly but spontaneously develops albu- independent of the cause or activity of the underlying
minuria and focal glomerulosclerosis. disease. Recent studies have indicated that the glomeru-Methods. Five-week-old non-albuminuric Thy-1.1 transgenic
lar epithelial cells, the so-called podocytes, may play anand non-transgenic control mice were injected with anti-APA
important role in the induction of proteinuria as well asand anti-Thy-1.1 mAb or saline. Albuminuria was measured
at days 1, 7, 14 and 21. At day 21 kidneys were processed for in the development of focal glomerulosclerosis [3–11].
light microscopy, immunofluorescence, and electron micros- One issue still debated is whether proteinuria is the cause
copy. or the consequence of focal glomerulosclerosis [2, 12].
Results. Injection of anti-APA and anti-Thy1.1 mAb in
In their endeavor to study the function of the Thy-1Thy-1.1 transgenic mice induced an albuminuria at day 1 that
antigen, Kollias et al have generated transgenic mice thatpersisted at day 21. The acute albuminuria after injection of
anti-APA mAb was more prominent but transient in non- ectopically express the Thy-1.1 antigen [13–16]. Some of
transgenic mice. In non-trangenic mice no albuminuria could these transgenic mice expressed the Thy-1.1 antigen on
be induced with anti-Thy 1.1 mAb. Light microscopy revealed the podocytes. These mice slowly and spontaneously de-
normal glomeruli at day 1 in all transgenic mice, however, at
veloped albuminuria and focal glomerulosclerosis [15].day 21 advanced glomerulosclerotic lesions were seen in mice
Injection of monoclonal antibody (mAb) directed againstinjected with either anti-APA mAb (3719% of glomeruli
the Thy-1.1 antigen caused an acute albuminuria accom-affected) or anti-Thy-1.1 mAb (715%). Non-transgenic mice
did not reveal sclerotic lesions at any time investigated. In the panied by effacement of podocytic foot processes [17].
transgenic mice the percentage of focal glomerulosclerosis at Normal mice do not express the Thy-1.1 antigen in the
day 21 did not correlate with albuminuria at day 21. However, kidney, in contrast to the rat, which expresses Thy-1.1we found a highly significant correlation between percentage
on mesangial cells [18].of focal glomerulosclerosis and the time-averaged albuminuria
We have recently reported another model of acuteover the three-week study period (P  0.001).
Conclusion. Injection of a combination of anti-APA or anti- albuminuria in mice, induced by injecting a combination
Thy-1.1 mAb into one mo old, non-albuminuric Thy-1.1 trans- of mAb directed against aminopeptidase A (APA), an
genic mice induces an acute albuminuria at day 1 that is accom- enzyme present on brush borders of proximal tubular
epithelial cells and podocytes [19]. APA is a transmem-
brane glycoprotein of about 130 kD, the best knownKey words: mouse model, transgene, podocyte injury, albuminuria,
sclerosis, aminopeptidase A, progressive renal disease. function of which is the degradation of angiotensin (Ang)
II to Ang III [20–24]. In the anti-APA model albuminuriaReceived for publication August 3, 2001
is not mediated by complement, inflammatory cells orand in revised form February 25, 2002
Accepted for publication February 27, 2002 coagulation factors [21]. Our recent studies demonstrated
that the albuminuria in this anti-APA model in mice is 2002 by the International Society of Nephrology
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not dependent on the presence of Ang II, but is initiated centrations were measured by the method of Lowry et
al [31].by the binding of the injected mAb to the podocytic
antigen APA as described for other models in rats and Antibodies used for the immunohistological detection
of glomerular localized antigens and injected antibodiesmice [19, 25–29]. Only certain combinations of anti-APA
mAb were able to induce an albuminuria, indicating that are listed in Table 1.
binding of the mAb to specific epitopes on APA is respon-
Animal experimentssible for the enhanced glomerular permeability [19].
Our data indicate that both anti-APA and anti-Thy-1.1 Untreated Thy-1.1 transgenic mice and control non-
transgenic mice were studied from five weeks after birthmAb induce an acute albuminuria in non-albuminuric,
5-week-old Thy-1.1 transgenic mice. Within three weeks until week 26 to determine the natural course of devel-
opment of albuminuria and focal glomerulosclerosis. Al-these mice then develop focal glomerulosclerosis with
characteristic lesions being present in the majority of buminuria was measured at regular intervals. At week
26 the mice were killed and their kidneys processedglomeruli. We feel that this model is very suitable to
further study the role of proteinuria and podocytic injury for light microscopy, immunofluorescence, and electron
microscopy.in the development of focal glomerulosclerosis.
Induction of an acute albuminuria. Experiments were
done in transgenic mice directly after weaning (week 5),
METHODS
at a time point when albuminuria was absent. Control
Animals experiments were done in non-transgenic littermates.
Four experimental groups were designed, each consistingHeterozygous Thy-1.1 transgenic mice were kindly
provided by Dr. D.J. Evans (T6) [15]. These mice were of six to nine animals. Group A received 4 mg of a com-
bination of two anti-APA mAb (ASD37/41; ratio 1:1)generated by injecting hybrid human-mouse Thy-1.1
genes into pronuclei of zygotes of Thy-1.2 CBA  intravenously (IV). Group B mice were injected with 4
mg of a single anti-APA mAb (ASD37). Group C miceC57Bl/10 parents [15]. We have used mice that abnor-
mally express the gene in podocytes, resulting in the received 4 mg of anti-mouse Thy-1.1 mAb (19XE5), and
group D mice served as controls receiving 0.5 mL ofpresence of the Thy-1.1 antigen on the podocytes (Fig. 1).
Non-transgenic (/) mice were used as controls. All saline IV.
In all mice albuminuria was measured at day 1, andmice were bred in our animal facility. Breading pairs
always consisted of a heterozygous (/) transgenic weeks 1, 2 and 3. At day 1, one mouse of each group was
killed after urine collection and the kidneys removedmouse and its non-transgenic counterpart. To identify
transgenic (/) and non-transgenic (/) mice, the and processed for histology. After urine collection at
week 3, all remaining mice were killed and the kidneyspresence of the transgene was examined by PCR on
genomic DNA obtained from the tail, with a forward processed for light microscopy. Fragments of the kidneys
of three mice of each group also were processed forprimer: 5-CGCCTGAGTCCTGATCTCC-3 and a re-
verse primer: 5-AACCTGCATCTTCACTGGGT-3. immunofluorescence and electron microscopy.
The presence of the transgene resulted in a specific 834
Measurement of albuminuriabp band.
BALB/c nu/nu mice, used for the production of rat Albuminuria, as a sign of glomerular protein leakage,
was measured in urine samples obtained by placing theanti-mouse Thy-1.1 (19XE5) mAb as ascites, were origi-
nally obtained from the Jackson Laboratory (Bar Har- animals in individual cages during 18 hours [32]. During
their confinement in the cages they had only access tobor, ME, USA), and bred in our animal facility.
tap water. Urinary albumin concentrations were mea-
Antibodies sured by radial immunodiffusion, using a goat antiserum
against mouse albumin [32, 33].For in vivo experiments two rat anti-mouse APA mAb
(ASD37 and ASD41) [19] and a mouse anti-mouse
Light microscopy, immunofluorescence, andThy-1.1 mAb (19XE5: subclass IgG3) [30] were used.
electron microscopy19XE5 was produced as ascites in BALB/c, nu/nu mice
and the Ig fraction enriched by 50% ammonium sulfate After removal of the kidneys small fragments were
fixed in Bouin’s solution for light microscopy, dehy-precipitation. ASD37 and ASD41 were generated in vitro
by hollow fiber culture, purified by Protein A column drated and embedded in paraplast (Amstelstad, Amster-
dam, The Netherlands) and 4 m sections were stainedaffinity chromatography and concentrated (Nematology
Department, Agriculture University Wageningen, The with periodic acid Schiff (PAS) and silver methenamine,
as described before [32]. At least 40 glomeruli were eval-Netherlands). All mAb were decomplemented at 56C
for 45 minutes and sterilized by the passage through a uated for the presence of podocytic hypertrophy, synech-
iae, sclerosis or hyalinosis, and the percentage of glomer-sterile 0.2 m filter, and stored at 80C. Protein con-
uli with these morphologic characteristics was calculated
(glomerulosclerosis score).
For immunofluorescence (IF), kidney fragments were
snap frozen in liquid nitrogen, and 2 m cryostat sections
were used. The binding of the injected anti-APA mAb
and anti-Thy-1.1 mAb as well as the presence of mouse
C3 and Ig were examined in direct IF after incubation
of the slides with fluorescein isothiocyanate (FITC)-
labeled, subclass-specific polyclonal or monoclonal anti-
bodies (Table 1). The expression of APA and Thy-1.1
was studied by indirect IF by using the primary antibod-
ies followed by FITC-labeled secondary antibodies as
listed in Table 1. Subclass-specific FITC-labeled antibod-
ies were employed in order to avoid cross reactivity.
Fig. 1. Expression of the Thy-1.1 transgene on podocytes of a kidney
of an untreated Thy-1.1 transgenic mouse as demonstrated by indirect
immunofluorescence with a mouse anti-Thy-1.1 monoclonal antibody
(mAb; 19XE5; 600).
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Fig. 3. Light microscopic pictures of Thy-1.1 transgenic mice injected with 4 mg of a combination of anti-aminopeptidase A mAb (ASD37/41).
(A) One day after injection of the mAb no glomerular lesions could be observed. In some tubuli protein casts are observed. (B) Low power view
with sclerotic lesions in some glomeruli (arrows) and tubulointerstitial damage around these glomeruli at day 21. (C ) Glomerulus with prominent
podocytic hypertrophy and swelling at day 21. In the enlarged podocytes many cytoplasmic vacuoles can be observed. (D) At day 21 typical
glomerulosclerotic lesions are present in other glomeruli such as increase of mesangial matrix and cells, accumulation of hyaline material, and
adhesions of the capillary tuft to Bowman’s capsule (methenamine silver staining; A, B 400; C, D 900).
Preliminary studies showed that these secondary anti- described before [19]. We observed similar blood pres-
bodies were very specific with no reactivity to other anti- sures in the normal range in Thy-1.1 transgenic mice and
gens as listed in Table 1. The expression of APA, for in wild-type littermates (not shown).
instance, was examined by indirect IF with an anti-APA In five-weeks-old mice there was no evidence of albu-
mAb (ASD38; subclass IgG2B) that was of a different minuria or focal glomerulosclerosis. Expression of APA
subclass and did not affect the binding of the two anti- as detected by immunofluorescence did not differ be-
APA mAb (ASD37 and 41; IgG2A) followed by FITC- tween transgenic and non-transgenic mice. By electron
labeled sheep anti-rat IgG2B. The sections were examined microscopy there were no abnormalities with respect to
in a fluorescence microscope (Leitz, Letzlar, Germany), foot processes of the podocytes.
and the staining intensity recorded semiquantitatively Results of albuminuria measured in the four experi-
on a scale from 0 to 4, as described before [32]. mental groups of transgenic and non-transgenic mice are
For electron microscopy, small pieces of cortex were presented in Table 2. Saline-injected transgenic mice
fixed in 2.5% glutaraldehyde dissolved in 0.1 mol/L so- demonstrated minor albuminuria at day 1 that gradually
dium cacodylate buffer, pH 7.4, for 24 hours at 4C, and increased to levels of 2949  1050 g/18 h at day 21.
washed in the same buffer [32]. The tissue fragments Albuminuria did not change in non-transgenic control
were postfixed in cacodylate-buffered 1% OsO4 for one mice. Injection of 4 mg of the combination of anti-APA
hour, dehydrated, and embedded in Epon 812 (Merck, mAb ASD37/41 (ratio 1:1) into Thy-1.1 transgenic mice
Darmstadt, Germany). Ultrathin sections were cut on induced a moderate acute albuminuria of 4828  1346
an ultratome (LKB instruments, Bromma, Sweden) and g/18 h at day 1. This albuminuria persisted and even
stained with 4% uranyl acetate for 45 minutes and with increased during the following weeks, averaging 8994 
lead citrate for two minutes at room temperature. The 1465 g/18 h at day 21. In contrast, albuminuria in non-
sections were examined in an electron microscope transgenic mice was very high at day 1 (48,466  9158
(JEOL 1200 EX2; JEOL, Tokyo, Japan). g/18 h), but rapidly dropped to low levels after seven
days. If 4 mg of a single anti-APA mAb (ASD37) wasStatistical analysis
administered to Thy-1.1 transgenic mice, a slight albu-
For statistical analysis, analysis of variance (ANOVA) minuria could be induced at day 1 (441  43 g/18 h),
was used and group comparisons were done with the that gradually increased to 7729  2,547 g at day 21.
Tukey-Kramer test. P values 0.05 were regarded as Injection of 4 mg of anti-Thy-1.1 mAb into Thy-1.1 trans-
significant. For correlations Spearman’s r was calculated. genic mice evoked a massive albuminuria of 47,648 
Time-averaged albuminuria was calculated after log- 1409 g/18 h at day 1. However, albuminuria dropped
transformation. All values are expressed as means 
to levels of 9665  1270 g/ 18 h at day 21, values com-
SEM (albuminuria) or SD (glomerulosclerosis score).
parable to the amounts of albuminuria in the other
groups of transgenic mice. Injection of anti-Thy-1.1 mAb
RESULTS into non-transgenic mice had no effect on the normal
physiological albuminuria.Albuminuria was measured regularly in untreated
At day 1 no glomerular abnormalities were observedThy-1.1 transgenic and non-transgenic mice over a 26
in light microscopy, with the exception of the presenceweek period (Fig. 2). Thy-1.1 transgenic mice gradually
of focal sclerotic lesions in 1 of 40 glomeruli in the kidneydeveloped albuminuria from week 7 onward. At week
of a transgenic mouse injected with ASD37 (Fig. 3A26 albuminuria averaged 6997  866 g /18 h (N 	 17)
and Table 3). Specifically, no inflammatory lesions wereas compared to 109  12 g/18 h (N 	 12) in control
observed in the mice with evident albuminuria. By IFnon-transgenic mice. At week 26, evidence of focal glo-
there was no evidence of deposition of mouse comple-merulosclerosis was found in 17  6% of glomeruli in
ment or Ig, except for the presence of a few mesangialthe transgenic mice as compared to none in the non-
deposits in all groups. Injection of the combinationtransgenic controls.
ASD37/41 in the Thy-1.1 transgenic and non-transgenicIntra-arterial blood pressures were measured after
canulation of the femoral artery in anesthesized mice as mice induced a fine granular binding of the mAb along
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Table 1. Antibodies used for the detection of injected antibodies and glomerular antigens
Antigena Primary antibodya Dil. Supplierb Secondary antibody Dil. Supplier
Antibodies injected
Anti-mouse Thy-1.1 mAb (19XE5) Sheep anti-mouse IgG3-FITC 25 Instruchemie —
Anti-mouse APA mAb (ASD37/41) Sheep anti-rat IgG2a-FITC 25 Serotec —
Anti-mouse APA mAb (ASD37) Sheep anti-rat IgG2a-FITC 25 Serotec —
Glomerular antigens
Thy-1.1  1.2 Rat anti-mouse (59AD2.2; IgG2a) 1 (30) Sheep anti-rat IgG2a-FITC 25 Serotec
APA Rat anti-mouse APA mAb (ASD38; IgG2b) 1 (21) Sheep anti-rat IgG2b-FITC 100 Serotec
Mouse-Ig Goat anti-mouse IgG1-FITC 25 Nordic —
Mouse-C3 Goat anti-mouse C3-FITC 40 Nordic —
Proliferation markers
PCNA Mouse mAb (PC10; IgG2a) 25 Dako Goat anti-mouse IgG2a 25 Nordic
Ki-67 antigen Mouse anti-human (MIB-1; IgG1) 10 Dako Goat anti-mouse IgG1 25 Nordic
Abbreviations are: mAb, monoclonal antibodies; Dil., dilution; APA, aminopeptidase A; PCNA, proliferating cell nuclear antigen.
a Code and subclass are in parentheses
b Serotec (Oxford, UK); Instruchemie (Hilversum, The Netherlands); Nordic (Tilburg, The Netherlands); Dako A/S (Glostrup, Denmark)
pattern was identical to the presence of the Thy-1.1 anti-
gen as revealed by immunofluorescence on kidney sec-
tions of untreated Thy-1.1 transgenic mice (Fig. 1), indi-
cating that the injected mAb were diffusely bound on
the cell membrane of the podocyte. The binding of the
anti-Thy-1.1 mAb had no effect on the presence of the
Thy-1.1 antigen at day 1 as demonstrated by a different
specific anti-Thy-1 mAb with another subclass (not
shown). Injection of anti-Thy-1.1 mAb in the non-trans-
genic mice understandably did not lead to binding to the
podocytes or other renal cells.
By electron microscopy extensive fusion of the foot
processes with mild vacuolization of the podocytic cyto-
plasm could be detected at day 1 in the glomeruli of trans-
genic mice injected with anti-Thy-1.1 mAb (Fig. 6A).
Fig. 2. Albuminuria expressed as the amount of albumin (g) excreted No evidence of podocytic detachment or denudation of
during 18 hours in untreated Thy-1.1 transgenic (solid line) mice and
the GBM was found, and no immune complexes werenon-transgenic (dotted line) mice. Albuminuria was regularly measured
between weeks 5 and 26. The dashed line reflects the upper limit of observed at the epithelial side of the glomerular base-
physiologic albuminuria. ment membrane. Non-transgenic mice administered
anti-Thy-1.1 mAb did not show any ultrastructural alter-
ations. Thy-1.1 transgenic and non-transgenic mice in-
jected with ASD37/41 showed segmental fusion of thethe capillary wall in a membranous pattern as described
podocytic foot processes (Fig. 6B). There were no differ-before (Fig. 4A) [19]. In addition, the anti-APA mAb
ences between these mice. There was no evidence ofbound to the brush borders of tubular epithelial cells
cytoplasmic vacuolization. Mice injected with ASD37 orwith signs of uptake of the mAb in vesicles and shedding
saline did not demonstrate ultrastructural damage.into the lumina of proximal tubules and binding to the
At day 21 all transgenic mice showed some evidencebasolateral cell membranes of these cells as described
of focal glomerulosclerosis in light microscopy (Fig. 3 B,before [19]. Injection of ASD37/41 changed the normal
C, D). However, abnormalities were limited to a fewhomogeneous localization of APA on the podocytes (not
glomeruli of transgenic mice injected with either salineshown) slightly into a more fine granular pattern at day
or ASD37 (glomerulosclerosis score 4  3% and 6 1 along the capillary wall comparable to the binding
3%, respectively). In contrast abundant glomeruloscle-pattern of the injected mAb (Fig. 4B) [19]. The adminis-
rosis was observed in mice injected with the combinationtration of ASD37 caused a more homogeneous binding
of anti-APA mAb or anti-Thy-1.1 mAb (glomeruloscle-along the capillary wall and binding to the brush borders
rosis score of 37  19% and 71  5%, respectively). Inand the basolateral cell membranes of proximal tubular
a few glomeruli prominent podocytic swelling was seenepithelial cells as described before [19]. Anti-Thy-1.1
with activated nuclei, vacuolization of expanded cyto-mAb in Thy-1.1 transgenic mice bound in a homogeneous
pattern to the podocytes at day 1 (Fig. 5). The staining plasm and collapse of the glomerular tuft (Fig. 3C), while
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Table 2. Albuminuria in Thy-1.1 transgenic (tg) and non-transgenic (non-tg) mice injected with anti-aminopeptidase A (APA)
or anti-Thy-1.1 mAb or saline
ASD 37/41 ASD37 Anti-Thy-1.1 Saline
Time tg non-tg tg non-tg tg non-tg tg non-tg
Day 1 4,8281,346b,d 48,4669,158 44143 17225 47,6481,409c,e,f 7013 19239 19228
(6) (5) (6) (5) (7) (4) (9) (5)
Week 1 14,198971 704422 1,493584 14227 24,0792,165 785 845305 14226
(5) (4) (5) (5) (5) (3) (8) (4)
Week 2 11,3071,742 10924 3,1051,081 9812 12,0101,432 427 1,384548 104178
(5) (4) (5) (5) (5) (3) (8) (4)
Week 3 8,994456a 12023 7,7292,547 479382 9,6651,270a 412 2,9491,050 1204
(5) (4) (5) (5) (5) (3) (8) (4)
At week 5 after birth, mice were injected intravenously with 4 mg of a combination of two anti-APA mAb (ASD37/41; ratio 1:1), 4 mg of a single anti-APA mAb
(ASD37), 4 mg of anti-Thy-1.1 mAb (19XE5), or saline. Values of albuminuria are expressed as g albumin excreted during an 18 hour period and given as means 
SEM. Number of mice in each group is given between parentheses. For comparison, non-treated transgenic mice spontaneously develop albuminuria that averages
6997  66 g/18 h at 26 weeks, whereas in non-transgenic mice the respective value amounts to 109  2 g/18 h.
a P 
 0.05, b P  0.01, c P  0.001 vs. saline
d P  0.05, eP  0.001 vs. ASD37
f P  0.001 vs. ASD37/41
Table 3. Glomerulosclerosis score in Thy-1.1 transgenic (tg) short-lasting albuminuria after injection of the combina-
and non-transgenic (non-tg) mice injected with
tion of anti-APA mAb (Table 3).anti-aminopeptidase A (APA), anti-Thy-1.1 mAb, or saline
By IF, at day 21 no or hardly any binding of the
Glomerulosclerosis %
injected anti-APA mAb (Fig. 4C) and anti-Thy-1.1 mAb
mAb injected Day 1 Day 21 (not shown) was observed. Likewise, the respective anti-
Anti-APA (ASD37/41) gens APA (Fig. 4D) and Thy-1.1 (not shown) were ex-
tg 0 (1) 379 (5)a,b
pressed in the glomeruli in a normal homogeneous pat-non-tg 0 (1) 0 (4)
Anti-APA (ASD37) tern except for their absence in sclerotic lesions. Mouse
tg 2 (1) 63 (5) Ig and C3 were found in trace amounts in the mesangium,non-tg ND 0 (5)
Anti-Thy-1.1 a normal finding in these mice, suggesting that the induc-
tg 0 (1) 715 (5)a,b,c tion of the prolonged albuminuria and the development
non-tg 0 (1) 0 (3)
of focal glomerulosclerosis was not dependent on anSaline
tg 0 (1) 43 (8) autologous reaction to the injected anti-APA or Thy-1.1
non-tg 0 (1) 0 (4) mAb. Using mAb against two proliferation markers, that
At week 5 after birth, mice were injected intravenously with 4 mg of a combina- is, proliferating cell nuclear antigen (PCNA) and Ki-tion of two anti-APA mAb (ASD37/41; ratio 1:1), 4 mg of a single anti-APA
mAb (ASD37), 4 mg of anti-Thy-1.1 mAb (19XE5), or saline. Glomerulosclerosis 67, we could not find signs of glomerular (podocytic)
score is defined as the percentage of glomeruli with morphological signs of
epithelial cell proliferation in antibody treated transgenicpodocytic hypertrophy, synechia, sclerosis, or hyalinosis in at least 40 counted
glomeruli (mean  SD; number of mice studied). and non-transgenic mice (not shown). Occasional tubulara P  0.001 vs. saline
cell proliferative activity was observed only in the anti-b P  0.001 vs. ASD37
c P  0.001 vs. ASD37/41 body-treated transgenic mice. By electron microscopy
fusion of the podocytic foot processes was still present
at day 21 in the transgenic mice injected with anti-Thy-
1.1 or the combination of anti-APA mAb, now accompa-most affected glomeruli showed next to podocytic hyper-
nied by segmental sclerosis and deposition of electrontrophy variable segmental sclerosis, and/or accumulation
dense material (hyalinosis; Fig. 6C). The latter lesionsof hyaline material and synechiae (Fig. 3D). A few glo-
were more intensive in mice injected with the anti-Thy-meruli were small and revealed a simplified architecture.
1.1 antibodies. Of note, foot process effacement hadDependent on the number of glomeruli affected, stripes
disappeared in the non-transgenic mice injected with theof interstitial fibrosis and a mild mononuclear cell infil-
combination of the anti-APA mAb.trate accompanied the sclerosing glomeruli. The tubuli
As expected from Table 3, no correlation was foundwere focally dilated and contained protein casts. The
between the actual level of albuminuria and the percent-tubular epithelial cells were sometimes swollen and con-
age of glomerulosclerosis at day 21. However, we ob-tained eosinophilic resorption droplets. Vessels were
served a highly significant correlation between the per-normal. Non-transgenic mice did not demonstrate mor-
centage of glomerulosclerosis and the time-averagedphologic alterations at day 21; thus, notably, glomerulos-
clerotic lesions were absent in mice that had developed albuminuria (r 	 0.95, P  0.001; Fig. 7).
Fig. 4. Immunofluorescence pictures of kid-
neys of Thy-1.1 transgenic mice injected with
a combination of two anti-aminopeptidase A
(APA) mAb (ASD37/41). (A) Fine granular
binding of the anti-APA mAb along the capil-
lary wall is seen at day 1. A binding to the
brush borders of the proximal tubular epithe-
lial cells also can be observed with uptake in
apical vesicles and shedding in the tubular
lumina. In addition, the injected mAb bound
to the basolateral cell membranes of the proxi-
mal tubular epithelial cells. (B) Glomerular
APA shows a fine granular localization along
the glomerular capillary wall at day 1. APA
is also present on the brush borders of the
proximal tubular epithelial cells. (C ) At day
21 the mAb injected had disappeared com-
pletely. (D) APA in non-sclerosing parts of
the glomeruli shows a more homogeneous lo-
calization on podocytes at day 21. It is absent
around sclerosing lesions of a glomerulus
(arrow) (A, B 800, C 600, D 400).
DISCUSSION
Injection of a combination of mAb directed at the podo-
cytic antigen APA in Thy-1.1 transgenic mice caused an
acute albuminuria. This albuminuria persisted and her-
alded the development of focal glomerulosclerosis,
which was not accompanied with signs of podocytic pro-
liferative activity frequently seen in the collapsing variant
of focal glomerulosclerosis. Likewise, injection of a mAb
directed at the Thy-1.1 antigen that is ectopically ex-
pressed in Thy-1.1 transgenic mice caused an acute albu-
minuria that persisted and was accompanied by the de-
velopment of extensive focal glomerulosclerosis. In both
conditions the initial albuminuria was accompanied by
podocytic injury as reflected by the effacement of foot
processes. We found no correlation between the extent
of glomerulosclerosis after three weeks and the actual
Fig. 5. Immunofluorescence pictures of kidneys of Thy-1.1 transgenic
mice injected with 4 mg of anti-Thy-1.1 mAb. Strong homogeneous
binding of the injected anti-Thy-1.1 mAb to podocytes at day 1 (600).
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Fig. 7. Relationship between the time-averaged albuminuria over the
three-week period and the percentage of glomerulosclerosis (100 glo-
meruli counted).
level of albuminuria. In contrast, a highly significant cor-
relation was found between the extent of focal glomeru-
losclerosis and the time averaged albuminuria in the
preceding study period. The transient albuminuria that
was observed in non-transgenic mice did not result in
focal glomerulosclerosis. Taken together, our data sug-
gest that acute albuminuria accelerates the development
of focal glomerulosclerosis in Thy-1.1 transgenic mice.
This model of accelerated focal glomerulosclerosis may
help in better defining the relationship between podo-
cytic injury, albuminuria and focal glomerulosclerosis.
Furthermore, because of the fast rate at which glomeru-
losclerosis develops, this model seems well suited for
intervention studies.
Our data demonstrate that there is no clear relation-
ship between the actual level of albuminuria and the
number of glomeruli with sclerotic lesions. In the differ-
ent groups of transgenic mice albuminuria at day 21 was
quite similar, whereas there were marked differences in
the percentage of glomerulosclerosis. These observa-
tions would fit with the observations of Yoshioka, Shir-
aga and Yoshida, that proteinuria was the consequence
of leakage of proteins in “healthy nephrons” [34].
The injection of anti-APA mAb in non-transgenic
mice induced a massive acute albuminuria. However, this
albuminuria was short-lasting as we have noted before in
our model in BALB/c mice. Evidently, the alterations
in glomerular permeability are quickly reversed, and the
podocytic foot processes regain their normal shape. This
cytoskeleton proteins at the base of the podocytes is clearly visible.
Note some vacuoles in the podocytic cytoplasm. No electron dense
deposits are present between the fused foot processes and the glomeru-
lar basement membrane. (B) One day after injection of ASD37/41 only
a partial retraction of the foot processes of the podocytes can be seen.
No electron dense deposits can be demonstrated between the intact foot
processes or between fused foot processes and glomerular basement
Fig. 6. Electron microscope pictures of kidneys of Thy-1.1 transgenic membrane. (C ) At day 21 after injection of ASD37/41 a global retraction
mice injected with anti-Thy-1.1 or anti-aminopeptidase A (APA) (ASD37/ of the foot processes of the podocytes is now present. In addition
41) mAb. (A) Prominent retraction of the foot processes of podocytes accumulation of the extracellular matrix with destruction of the glomer-
one day after injection of the anti-Thy-1.1 mAb. Condensation of ular loop architecture can be seen (A, B 16,000, C 3000).
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short-lasting though heavy albuminuria is not sufficient Thy-1.1 mRNA and one line with high mRNA and lower
protein expression in podocytes (T11) do not developto induce focal glomerulosclerosis.
The situation is clearly different in the Thy-1.1 trans- albuminuria and focal glomerulosclerosis. This suggests
that the level of Thy-1.1 mRNA and protein expressiongenic mice. These mice spontaneously develop focal glo-
merulosclerosis, and this process can be enhanced by per- in podocytes might be the crucial factor in inducing the
enhanced glomerular permeability and accompanyingsistent albuminuria. The more severe the albuminuria,
the more glomeruli become abnormal. Notably, in the glomerulosclerosis [15]. Inability of the podocytes to en-
large or to replicate, and to withstand the increases intransgenic mice the injection of anti-APA antibodies in-
duced only a moderate albuminuria. However, this al- size or pressure of hyperfiltering glomeruli is one mecha-
nism of development of focal glomerulosclerosis [11].buminuria persisted without evidence of restoration of
glomerular permeability. We cannot explain why the al- The re-arrangement of foot processes is an active process
dependent on various functions such as intracellular pro-buminuria induced by the anti-APA mAb was lower in
the transgenic mice than in the non-transgenic litter- tein transport, energy metabolism and involvement of
the cytoskeleton. A disturbance in podocyte functionmates. It is unlikely that hemodynamic changes are in-
volved, although we cannot exclude that intraglomerular could explain the inability of the transgenic mice to re-
store glomerular permselectivity after the first insult andpressures are lower in the transgenic animals. Theoreti-
cally, the differences could be explained by differences the ensuing enhanced focal glomerulosclerosis. Various
processes may be involved in the induction of the en-in the spatial resolution of the APA antigen on the podo-
cytes or impairment in the formation of immune aggre- hanced glomerular permeability for proteins and the
development of focal glomerulosclerosis, however, ourgates. There is no evidence for either concept, since we
observed no differences in APA immunofluorescence knowledge of the mechanisms involved is still insuffi-
cient. In recent years, several components of the podo-nor were there differences in the granular deposits.
Aminopeptidase A and Thy-1.1 are differently an- cyte and its related structures that bind them together
(slit diaphragms) and to the GBM (adhesion molecules)chored in the cell membranes of the podocytes. APA is
a transmembrane glycoprotein of about 130 kD that is have been defined to be related to the development of
the proteinuria or focal glomerulosclerosis, such as neph-coupled to the actin cytoskeleton [19, 21, 24, 35]. Thy-1.1
antigen, on the other hand, is normally bound to the rin, the CD2-associated protein, dystroglycans, podocin
and -actinin-4 [37–43]. These recent findings indicateouter leaflet of the cell membrane via glycosyl phosphati-
dyl inositol (GPI), and is not connected to actin. Cross the critical role of the podocyte in the development of the
nephrotic syndrome and focal glomerulosclerosis [37].linking Thy-1.1 and other GPI-antigens by antibodies
induces tyrosine phosphorylation of intracellular pro- Several animal models are now available in which the
introduction of a transgene or the modification of a geneteins, although the potential proteins linked to these
GPI-antigens that transmit the signal of phosphorylation in podocytes leads to a more or less severe albuminuria,
sometimes of nephrotic range, and focal glomeruloscle-are not fully known [36]. The different anchoring of the
two proteins in the cell membranes and the coupling to rosis frequently accompanied by focal interstitial fibrosis,
mononuclear cell infiltration and dilated tubuli [44–56].cytoskeletal proteins or different intracellular signaling
pathways may explain the different antigenic modulation Of particular interest are the Mpv17 gene inactivated mice
and the HIV transgenic mice, which show some clinicalas well as the extent of the albuminuria after binding of
the injected antibodies. Binding of anti-APA (ASD37/41 and morphologic resemblance to the Thy-1.1 transgenic
mice. The introduction of different ectopic transgenesmAb) to the podocytes resulted in a fine granular accu-
mulation of APA and administered mAb along the outer or the interruption of a preexisting gene in the podocytes
in these models most likely disturbs the normal podocyteside of the glomerular basement membrane (GBM) as
seen by IF and a moderate albuminuria. Binding of the physiology and seems to set in motion a common patho-
physiologic pathway, resulting in comparable clinical andmAb to the more movable Thy-1.1 protein, however,
had no effect on its diffuse presence on the cell mem- morphological alterations. The pathogenic mechanisms
in all these models are poorly understood at the moment,branes, but caused a higher albuminuria.
How the insertion of the Thy-1.1 construct in podo- but since they resemble some forms of focal glomerulo-
sclerosis in humans (such as HIV nephropathy) thesecytes leads to glomerular damage is not clear at the
moment. It may be that the podocytes in the transgenic mice are of utmost importance for the elucidation of the
altered podocytic function. In the transgenic model ofmice are intrinsically altered just by the insertion of the
Thy-1.1 gene. The T6 transgenic line is not unique, how- HIV-associated nephropathy, a severe dedifferentiation
of podocytes due to HIV transgene expression was foundever, since two other transgenic lines (T12 and mhT4)
with high podocytic Thy-1.1 mRNA and protein expres- resulting in dysregulation of the epithelial cell cycle, that
resembles the podocytic alterations as seen in humanssion developed albuminuria and focal glomerulosclerosis
[15]. Other transgenic lines demonstrating low levels of infected with HIV [46, 56]. The Thy-1.1 transgenic model
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protein: Structure, distribution and ontogeny. Lab Invest 54:122–has an advantage over all other models of glomeruloscle-
135, 1986
rosis in mice, since the introduced transgene is solely ex- 14. Giguere V, Isobe KJ, Grosveld F: Structure of the murine Thy-1
gene. EMBO J 4:2017–2024, 1985pressed diffusely in the cell membranes of the podocytes.
15. Kollias G, Evans DJ, Ritter M, et al: Ectopic expression ofThis enables us to accelerate the albuminuria and partic-
Thy-1 in the kidneys of transgenic mice induces functional and
ularly the development of focal glomerulosclerosis by in- proliferative abnormalities. Cell 51:21–31, 1987
16. Vidal M, Morris R, Grosveld F, Spanopoulou E: Tissue specificjection of antibodies against Thy-1.1 antigen. In addition,
control elements of the Thy-1 gene. EMBO J 9:833–840, 1990the severity of the clinical and morphological alterations
17. Ebrahim H, Evans DJ: Antibody induced injury to podocytes with
can be modulated by the amount of antibody injected. proteinuria and foot process swelling in a transgenic (T16) mouse.
Int J Exp Path 80:77–86, 1999In conclusion, we have described in this study that
18. Paul LC, Rennke HG, Milford EL, Carpenter CB: Thy-1.1 ininjection of mAb directed to different podocytic anti-
glomeruli of rat kidneys. Kidney Int 25:771–777, 1984
gens, that is, APA and the Thy-1.1 transgene, into young 19. Mentzel S, van Son JPHF, Dijkman HBPM, et al: Induction of
albuminuria in mice: Synergistic effect of two monoclonal antibod-non-albuminuric Thy-1.1 transgenic mice induces acute
ies directed to different domains of aminopeptidase A. Kidney Intalbuminuria that is followed by an accelerated focal glo-
55:1335–1347, 1999
merulosclerosis. The Thy-1.1 transgenic mice might pro- 20. Wu Q, Lahti JM, Air GM, et al: Molecular cloning of the murine
BP-1/6C3 antigen: A member of the zinc-dependent metallopepti-vide an excellent animal model to study the relationship
dase family. Proc Natl Acad Sci USA 87:993–997, 1990between podocytic injury, proteinuria and the develop-
21. Assmann KJM, van Son JPHF, Dijkman HBPM, Koene RAP: A
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